Holen Sie sich die Stockscreener-App
3.435
0.44%
0.015
Schlusskurs vom Vortag:
$3.42
Offen:
$3.5
24-Stunden-Volumen:
365.76K
Relative Volume:
0.10
Marktkapitalisierung:
$370.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-258.08M
KGV:
-1.2491
EPS:
-2.75
Netto-Cashflow:
$-202.32M
1W Leistung:
+8.02%
1M Leistung:
+8.70%
6M Leistung:
-34.82%
1J Leistung:
-79.92%
1-Tages-Spanne:
$3.42
$3.5739
1-Wochen-Bereich:
$3.10
$3.74
52-Wochen-Spanne:
$2.19
$18.89
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Firmenname
Rocket Pharmaceuticals Inc
Sektor
Branche
Telefon
646-440-9100
Adresse
350 FIFTH AVENUE, NEW YORK, NY
Vergleichen Sie RCKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.435 | 369.03M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.42 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.52 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.57 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
328.93 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-30 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-05-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-28 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-28 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | Herabstufung | Needham | Buy → Hold |
| 2025-05-27 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-30 | Eingeleitet | Wedbush | Outperform |
| 2024-12-18 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-11-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-11-01 | Eingeleitet | BTIG Research | Buy |
| 2022-07-08 | Eingeleitet | Raymond James | Outperform |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2021-02-18 | Eingeleitet | Needham | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2019-11-06 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-04-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
| 2019-02-05 | Eingeleitet | Oppenheimer | Outperform |
| 2018-09-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-07-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
Will Rocket Pharmaceuticals Inc. Equity Warrant stock benefit from upcoming earnings reportsJuly 2025 Highlights & Community Supported Trade Ideas - newser.com
Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Rocket Pharmaceuticals Inc. Equity Warrant stock bottoming outQuarterly Risk Review & Free Real-Time Market Sentiment Alerts - newser.com
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Will Rocket Pharmaceuticals Inc. stock go up soonJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
Should you hold or exit Rocket Pharmaceuticals Inc. now2025 Trading Volume Trends & Real-Time Buy Signal Notifications - newser.com
Published on: 2025-10-10 06:17:17 - newser.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Receives "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Published on: 2025-10-10 04:39:16 - newser.com
Building trade automation scripts for Rocket Pharmaceuticals Inc. Equity Warrant2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
How to use Fibonacci retracement on Rocket Pharmaceuticals Inc. Equity WarrantMarket Volume Report & High Win Rate Trade Alerts - newser.com
How sentiment analysis helps forecast Rocket Pharmaceuticals Inc. Equity WarrantPortfolio Update Report & Weekly High Potential Stock Alerts - newser.com
Will Rocket Pharmaceuticals Inc. (9IP1) stock profit from fiscal stimulusEarnings Beat & Intraday High Probability Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Investors to Reach Out - ACCESS Newswire
How to manage a losing position in Rocket Pharmaceuticals Inc. Equity Warrant2025 AllTime Highs & Free Technical Confirmation Trade Alerts - newser.com
Published on: 2025-10-09 05:44:17 - newser.com
Published on: 2025-10-09 03:18:17 - newser.com
Can a trend reversal in Rocket Pharmaceuticals Inc. Equity Warrant lead to recovery2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - newser.com
Automated trading signals detected on Rocket Pharmaceuticals Inc. Equity WarrantWeekly Market Report & Safe Entry Point Identification - newser.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
What drives Rocket Pharmaceuticals Inc stock priceBollinger Bands Signals & Free Dynamic Capital Growth - earlytimes.in
Rocket Pharmaceuticals Pulls BLA for Fanconi Anemia Gene Therapy RP-L102 - CGTLive®
How Rocket Pharmaceuticals Inc. Equity Warrant stock reacts to global recession fearsJuly 2025 Trends & Risk Controlled Daily Trade Plans - newser.com
Is Rocket Pharmaceuticals Inc. Equity Warrant stock ready for a breakout2025 Trading Recap & Verified Swing Trading Watchlists - newser.com
Rocket Pharmaceuticals Inc. Equity Warrant stock volume spike explainedPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com
Using AI based signals to follow Rocket Pharmaceuticals Inc. Equity WarrantMarket Performance Summary & Weekly High Conviction Ideas - newser.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Reach Out - ACCESS Newswire
Combining price and volume data for Rocket Pharmaceuticals Inc. Equity WarrantEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Real time social sentiment graph for Rocket Pharmaceuticals Inc. Equity WarrantTrade Signal Summary & Daily Chart Pattern Signal Reports - newser.com
Is Rocket Pharmaceuticals Inc. Equity Warrant stock positioned well for digital economyGap Up & Community Verified Trade Signals - newser.com
Understanding Rocket Pharmaceuticals Inc. Equity Warrant’s price movementJuly 2025 PreEarnings & Accurate Intraday Trade Tips - newser.com
Is now a turning point for Rocket Pharmaceuticals Inc.2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Published on: 2025-10-05 06:51:42 - newser.com
Is Rocket Pharmaceuticals Inc. Equity Warrant stock resilient to inflationMarket Activity Report & Real-Time Volume Spike Alerts - newser.com
Is Rocket Pharmaceuticals Inc. (9IP1) stock a buy for dividend portfolios2025 Retail Activity & Safe Entry Zone Identification - newser.com
Comparing Rocket Pharmaceuticals Inc. Equity Warrant in custom built stock radarsJuly 2025 WrapUp & Weekly Sector Rotation Insights - newser.com
Rocket Pharmaceuticals board member Pedro Granadillo resigns - StreetInsider
Leerink Partners Maintains Rocket Pharmaceuticals (RCKT) Market Perform Recommendation - Nasdaq
Rocket Pharmaceuticals announces board resignation of Pedro Granadillo - Investing.com
Rocket Pharmaceuticals Pulls FDA Filing for Rare Blood Disorder Gene Therapy - MedCity News
Rocket Pharmaceuticals (RCKT) Withdraws U.S. Filing for Gene The - GuruFocus
Leerink Partners Adjusts Rocket Pharmaceuticals Price Target to $7 From $9, Maintains Market Perform Rating - MarketScreener
Rocket Pharma pulls BLA for gene therapy RP-L102 in the USA - The Pharma Letter
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy - Stocktwits
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $7.00 by Analysts at Leerink Partners - MarketBeat
RCKT: Analyst Lowers Price Target for Rocket Pharmaceuticals | R - GuruFocus
Leerink Partners Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating, Announces Target Price $7 - 富途牛牛
Rocket Pharmaceuticals (RCKT) Halts U.S. Application for Gene Th - GuruFocus
Using R and stats models for Rocket Pharmaceuticals Inc. Equity Warrant forecasting2025 Market Outlook & Low Risk Profit Maximizing Plans - newser.com
Rocket Pharmaceuticals withdraws US application for blood disorder gene therapy - MarketScreener
Rocket Pharmaceuticals withdraws BLA for gene therapy RP-L102 in the US - Investing.com
Finanzdaten der Rocket Pharmaceuticals Inc-Aktie (RCKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rocket Pharmaceuticals Inc-Aktie (RCKT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Militello John | See Remarks |
Aug 18 '25 |
Sale |
3.06 |
699 |
2,142 |
56,285 |
| Militello John | See Remarks |
Aug 19 '25 |
Sale |
3.00 |
361 |
1,082 |
55,924 |
| Schwartz Jonathan David | See Remarks |
Aug 18 '25 |
Sale |
3.06 |
1,680 |
5,149 |
222,414 |
| Schwartz Jonathan David | See Remarks |
Aug 19 '25 |
Sale |
3.00 |
805 |
2,412 |
221,609 |
| Wilson Martin | General Counsel |
Aug 18 '25 |
Sale |
3.06 |
1,004 |
3,077 |
136,050 |
| Wilson Martin | General Counsel |
Aug 19 '25 |
Sale |
3.00 |
588 |
1,762 |
135,462 |
0.11%
2.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):